YieldMax MRNA Option Income Strategy ETF (MRNY)
ARCA ARCA Primary 
MRNY: The Yield Is Too Aggressive For Long-Term Sustainability
YieldMax MRNA Option Income Strategy ETF offers a high-yield, high-risk profile, best used for tactical income generation rather than long-term holding. MRNY's 105%+ yield is driven by an aggressive option-writing strategy, but NAV erosion is inevitable due to capped upside and full downside exposure. Total returns are highly dependent on timing; MRNY underperforms MRNA in strong rallies and fails to buffer sharp drawdowns effectively.
MRNY: Strong Income Run Masks Rising Downside Risk
YieldMax MRNA Option Income Strategy ETF (MRNY) is maintained as a Sell due to heightened downside risk and overvalued pipeline optimism. MRNY's aggressive 100% covered call strategy captures some upside but offers limited downside protection and lower income in flat markets. Moderna's (MRNA) revenue base is structurally declining, with oncology pipeline progress already priced into an elevated EV/revenue multiple.
MRNY: Jumping On Big Moderna Move
YieldMax MRNA Option Income Strategy ETF has rebounded sharply from historic lows, driven by positive catalysts in underlying Moderna. MRNY's distributions have increased alongside MRNA's share price resurgence, demonstrating the ETF's alignment with its underlying performance. Recent MRNA catalysts include partnership rumors, better-than-expected Q3 2025 revenue, EMA COVID shot approval, and promising cancer therapy trial results.
